{
  "docId": "019de072-a06b-75fe-abfc-06d6c9b36d69",
  "docSlug": "20a8e4b0fa87449fed1951c46c728b45",
  "documentTitle": "argenx SE | Results Presentation Deck | 21 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 21,
  "prevPage": 20,
  "nextPage": null,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a timeline-like visual to show the expansion of indications for the drug VYVGART.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-a06b-75fe-abfc-06d6c9b36d69/21",
  "deckHref": "/decks/019de072-a06b-75fe-abfc-06d6c9b36d69",
  "deckJsonHref": "/decks/019de072-a06b-75fe-abfc-06d6c9b36d69.json",
  "deckAnchorHref": "/decks/019de072-a06b-75fe-abfc-06d6c9b36d69#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "Timeline of indications: gMG, ITP, Pemphigus, CIDP, Myositis, BP, Membranous Nephropathy, Lupus Nephritis, COVID-19-mediated POTS, Sjogren's Syndrome",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f30eb0c-9c3b-4aea-85c4-62c0bfee45d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "legend",
      "text": "Key: NEURO, HEME, SKIN, KIDNEY",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87d44fa9-e9b5-462c-8ec9-22006f4b6047",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.45,
        "y": 0.7
      },
      "kind": "list",
      "text": "4/4 (gMG, ITP, PV, CIDP) positive POC trials results; 3/3 (gMG-IV, gMG-SC, ITP) positive Phase 3 trials results; First launches in US and Japan in gMG",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17944de1-9e36-417d-83db-69c3d70cc89d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "ITP is the Second Indication with a Positive Phase 3 Read-out for VYVGART",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67b5cf95-e620-4fb8-9423-1c63270688ae",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "1f4cda55-46c4-4ed3-9b03-3302b8eec4b6",
      "evidence": "The slide uses a horizontal line to represent the progression of clinical indications over time.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}